8月25日，药明合联盘中上涨5.73%，报73.8港元/股，成交额1.43亿港元。
消息面上，公司于8月24日晚间发布中期业绩，截至6月30日止六个月实现收益37.01亿元人民币，同比增长37.0%；剔除汇率影响后同比增长41.5%。毛利13.71亿元，同比增长40.6%，毛利率由36.1%提升至37.0%；公司拥有人应占经调整纯利10.27亿元，同比增长37.4%。独立业务（不含东曜药业并表贡献）经调整纯利率由27.7%提升至28.9%，盈利质量进一步改善。此外，公司累计获得21个PPQ项目及2个商业化项目，未完成订单突破20亿美元，为后续增长提供订单支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.